The first step of the cooperation will consist of a feasibility test for the manufacturing of the drug, an infusion-administered alpha 1-proteinase inhibitor (API), from the European company’s raw materials, using Kamada’s proprietary manufacturing process.
Congenital emphysema is a disease caused by an inborn deficiency of the alpha1 protein. The API is produced by Kamada using the fourth fraction of human plasma.
Under the memorandum of understanding (MoU), Kamada grants the European company a limited-time option to buy a license for the production, registration and then the distribution of the product (following the completion of its development by Kamada) in major European markets. This is in addition to the possibility of using the Kamada facility for the API’s production.
David Tsur, Kamada’s CEO, said that the agreement is in line with Kamada’s strategy to promote cooperation with leading European pharmaceutical companies. This strategy has already led to advanced-stage partnerships with two leading pharmaceutical companies in France and Italy. Kamada expects the cooperation with the three European companies to generate both short and long-term revenues.